Literature DB >> 15064358

The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.

L B Pritzker1, M Scatena, C M Giachelli.   

Abstract

Endothelial cell survival and antiapoptotic pathways, including those stimulated by extracellular matrix, are critical regulators of vasculogenesis, angiogenesis, endothelial repair, and shear-stress-induced endothelial activation. One of these pathways is mediated by alpha(v)beta(3) integrin ligation, downstream activation of nuclear factor-kappaB, and subsequent up-regulation of osteoprotegerin (OPG). In this study, the mechanism by which OPG protects endothelial cells from death was examined. Serum-starved human microvascular endothelial cells (HMECs) plated on the alpha(v)beta(3) ligand osteopontin were protected from cell death. Immunoprecipitation experiments indicated that OPG formed a complex with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HMECs under these conditions. Furthermore, inhibitors of TRAIL, including recombinant soluble TRAIL receptors and a neutralizing antibody against TRAIL, blocked apoptosis of serum-starved HMECs plated on the nonintegrin attachment factor poly-d-lysine. Whereas TRAIL was unable to induce apoptosis in HMECs plated on osteopontin, the addition of recombinant TRAIL did increase the percentage of apoptotic HMECs plated on poly-d-lysine. This evidence indicates that OPG blocks endothelial cell apoptosis through binding TRAIL and preventing its interaction with death-inducing TRAIL-receptors

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064358      PMCID: PMC420106          DOI: 10.1091/mbc.e04-01-0059

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  53 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

Review 2.  Endothelial cell apoptosis in angiogenesis and vessel regression.

Authors:  S Dimmeler; A M Zeiher
Journal:  Circ Res       Date:  2000-09-15       Impact factor: 17.367

3.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types.

Authors:  X D Zhang; T Nguyen; W D Thomas; J E Sanders; P Hersey
Journal:  FEBS Lett       Date:  2000-10-06       Impact factor: 4.124

5.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

Authors:  R Nitsch; I Bechmann; R A Deisz; D Haas; T N Lehmann; U Wendling; F Zipp
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

6.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  M Jo; T H Kim; D W Seol; J E Esplen; K Dorko; T R Billiar; S C Strom
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

7.  TRAIL expression in vascular smooth muscle.

Authors:  B R Gochuico; J Zhang; B Y Ma; A Marshak-Rothstein; A Fine
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-05       Impact factor: 5.464

8.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

9.  Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.

Authors:  T J Yun; M D Tallquist; A Aicher; K L Rafferty; A J Marshall; J J Moon; M E Ewings; M Mohaupt; S W Herring; E A Clark
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

10.  Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis.

Authors:  F Aoudjit; K Vuori
Journal:  J Cell Biol       Date:  2001-02-05       Impact factor: 10.539

View more
  29 in total

Review 1.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

2.  Osteoclasts are important for bone angiogenesis.

Authors:  Frank C Cackowski; Judith L Anderson; Kenneth D Patrene; Rushir J Choksi; Steven D Shapiro; Jolene J Windle; Harry C Blair; G David Roodman
Journal:  Blood       Date:  2009-11-03       Impact factor: 22.113

3.  Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.

Authors:  J H Kang; H M Ko; J S Moon; H I Yoo; J Y Jung; M S Kim; J T Koh; W J Kim; S H Kim
Journal:  J Dent Res       Date:  2014-09-25       Impact factor: 6.116

4.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

Review 5.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 6.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

7.  Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

Authors:  Johnny S H Kwan; Yi-Hsiang Hsu; Ching-Lung Cheung; Josée Dupuis; Aude Saint-Pierre; Joel Eriksson; Samuel K Handelman; Aaron Aragaki; David Karasik; Peter P Pramstaller; Charles Kooperberg; Andrea Z Lacroix; Martin G Larson; Kam-Shing Lau; Mattias Lorentzon; Irene Pichler; Pak C Sham; Daniel Taliun; Liesbeth Vandenput; Douglas P Kiel; Andrew A Hicks; Rebecca D Jackson; Claes Ohlsson; Emelia J Benjamin; Annie W C Kung
Journal:  Hum Mol Genet       Date:  2014-07-30       Impact factor: 6.150

8.  Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Authors:  Irma Airoldi; Claudia Cocco; Nicola Giuliani; Marina Ferrarini; Simona Colla; Emanuela Ognio; Giuseppe Taverniti; Emma Di Carlo; Giovanna Cutrona; Vittorio Perfetti; Vittorio Rizzoli; Domenico Ribatti; Vito Pistoia
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

9.  TRAIL-deficient mice exhibit delayed regression of retinal neovascularization.

Authors:  Kristin E Hubert; Michael H Davies; Andrew J Stempel; Thomas S Griffith; Michael R Powers
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

10.  Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Authors:  Sean Morony; Yin Tintut; Zina Zhang; Russell C Cattley; Gwyneth Van; Denise Dwyer; Marina Stolina; Paul J Kostenuik; Linda L Demer
Journal:  Circulation       Date:  2008-01-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.